Elizabeth Garrett-Mayer to Farnesyltranstransferase
This is a "connection" page, showing publications Elizabeth Garrett-Mayer has written about Farnesyltranstransferase.
Connection Strength
0.088
-
A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia. Blood. 2007 Feb 15; 109(4):1387-94.
Score: 0.068
-
Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide. Blood. 2009 May 14; 113(20):4841-52.
Score: 0.020